Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7402885 | 0.92 | KMT2A (0.66) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL7403546 | 0.91 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL17130452 | 0.91 | KMT2A (0.60) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL6285024 | 0.90 | KMT2A (0.70) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL31031847 | 0.88 | KMT2A (0.63) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL1893763 | 0.88 | KMT2A (0.63) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL6375583 | 0.85 | KMT2A (0.66) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL31726952 | 0.84 | KMT2A (0.59) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL10018066 | 0.83 | KMT2A (0.58) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL163534 | 0.83 | KMT2A (0.67) | KMT2AEPHX2CASP3FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5710159-A | IMIDAZOLIN-2-YLAMINOPROPOXY)ISOXAZOL-5-CARBONYLAMINO-2 -BENZYLOXYCARBONYLAMINOPROPIONIC ACID AS ANTIINFLAMMATORY AGENTS, BONE DEGRADATION, TUMORS, METASTASES AND THROMBOSIS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |